A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis

Leukemia. 2019 Dec;33(12):2974-2978. doi: 10.1038/s41375-019-0524-7. Epub 2019 Jul 30.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Interferon-alpha / administration & dosage
  • Interferon-alpha / adverse effects
  • Interferon-alpha / therapeutic use*
  • Mesenteric Veins / pathology*
  • Polycythemia Vera / complications*
  • Polycythemia Vera / diagnosis
  • Polycythemia Vera / drug therapy*
  • Polycythemia Vera / etiology
  • Polyethylene Glycols / administration & dosage
  • Polyethylene Glycols / adverse effects
  • Polyethylene Glycols / therapeutic use*
  • Prospective Studies
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / adverse effects
  • Recombinant Proteins / therapeutic use
  • Thrombocythemia, Essential / complications*
  • Thrombocythemia, Essential / diagnosis
  • Thrombocythemia, Essential / drug therapy*
  • Thrombocythemia, Essential / etiology
  • Venous Thrombosis / diagnosis
  • Venous Thrombosis / etiology*
  • Venous Thrombosis / therapy

Substances

  • Interferon-alpha
  • Recombinant Proteins
  • Polyethylene Glycols
  • peginterferon alfa-2a